- Li has held key leadership roles at Amgen and Merck
- He was also a partner in the life sciences practice at Kleiner Perkins
- Frazier Life Sciences invests in biopharmaceutical companies
Frazier Life Sciences has named Dr. James Li as a venture partner.
Most recently, Li co-founded and was CEO of JW Therapeutics. Prior to that Li held key leadership roles at Amgen and Merck. He also worked as a partner in the life sciences practice at Kleiner Perkins Caufield & Byers.
“We are thrilled to welcome James to the team,” FLS managing partner Patrick Heron said in a statement. “We believe his deep breadth of experience in launching transformative therapies and navigating cross-border opportunities will add considerable value to our portfolio companies and investment strategies.”
Headquartered in Palo Alto, California, Frazier Life Sciences invests in companies that discover, develop and commercialize innovative biopharmaceuticals. It manages more than $3.9 billion in capital, including venture funds focusing on company creation and private companies and the long-only Public Fund focused on small and mid-cap public companies.
FLS closed on $987 million for Frazier Life Sciences XI in March 2022, exceeding its target of $800 million, according to fundraising data from affiliate title Buyouts. LPs in Fund XI include the 3M Company Pension Fund, Andrew W. Mellon Foundation, Bimah Foundation, John D. and Catherine T. MacArthur Foundation, Maryland State Retirement and Pension System, Penn Mutual Life Insurance Company, Richard King Mellon Foundation and The Leona M. and Harry B. Helmsley Charitable Trust, Buyouts reports.
Leave a Reply